What one share of Xilio Therapeutics holds
We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer. Leveraging our clinically-validated masking technology and capabilities, we are developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents.
Xilio Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.52 |
|---|---|
| Profit | −$1.54 |
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | −$4.32 |
| Cash and investments | $20.67 |
| Book value | $10.98 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$1,476 | $58.48 | −$1,023 | — | −$1,690 |
| 2021 | — | −$189.29 | $2.75 | −$204.40 | — | — |
| 2022 | — | −$45.09 | $0.95 | −$39.66 | — | $53.93 |
| 2023 | — | −$38.90 | $0.25 | −$35.19 | — | $18.68 |
| 2024 | $1.66 | −$15.24 | $0.01 | −$4.82 | — | $5.38 |
| 2025 | $5.24 | −$4.19 | $0.06 | −$0.66 | — | $7.79 |
Common questions about Xilio Therapeutics
How much does one share of Xilio Therapeutics earn?
Over the last 12 months, Xilio Therapeutics lost $1.54 for each share on $4.52 of sales.
Does Xilio Therapeutics pay a dividend?
Xilio Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Xilio Therapeutics’s book value per share?
Xilio Therapeutics’s book value is $10.98 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Xilio Therapeutics have?
Each share of Xilio Therapeutics has $20.67 of cash and investments, as of June 30, 2026.
What is Xilio Therapeutics’s free cash flow per share?
−$4.32 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Xilio Therapeutics bought back shares?
Xilio Therapeutics’s share count rose about 22243% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.